This ability of Bcl-2 inhibitors to overcome Btz resistance has not been described in the in vitro generated cell lines, however, none of them bear the t(11;14) translocation which sensitizes myeloma cells to Bcl-2 inhibitors. The gene discussed is CASC3; the disease is plasma cell myeloma.